Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Press Releases
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société NOVARTIS AG
07/22NOVARTIS : ESG Update - July 22, 2021
PU
07/21NOVARTIS : Yes ☐ No ☒ (Form 6-K)
PU
07/21NOVARTIS : Q2 Earnings Snapshot
AQ
07/21NOVARTIS : Download the interactive presentation (PDF 4.5 MB)
PU
07/21NOVARTIS : Q2 2021 results Media release English
PU
07/20NOVARTIS : pledges 10-year commitment with Morehouse School of Medicine, 26 Hist..
PU
07/16AUROBINDO PHARMA : Receives FDA Approval for Baclofen Tablets USP, 10 mg and 20 ..
AQ
07/14NOVARTIS : announces NEJM publication of positive Phase III REACH3 data for Jaka..
PU
07/02FEDERAL COURT DISMISSES ROCHE'S PMNO : Pirfenidone
AQ
06/28NOVARTIS : International AG Novartis Global Communications CH-4002 Basel Switzer..
PU
06/23NOVARTIS : Positive survival data for Novartis investigational radioligand thera..
PU
06/23NOVARTIS : Kesimpta data show long-term preservation of IgG/IgM levels and no in..
AQ
06/23NOVARTIS : and Hewlett Packard Enterprise join forces to advance Novartis global..
PU
06/22NOVARTIS : Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM le..
PU
06/14NOVARTIS : investigational oral therapy iptacopan (LNP023) shows benefit as mono..
AQ
06/07NOVARTIS : announces new interim analysis Phase II data for iptacopan in rare ki..
PU
06/03NOVARTIS : Kymriah pivotal trial demonstrates strong response rates and a remark..
AQ
05/27ETON PHARMACEUTICALS : Particularity In Petitions Produces Positive Post-Grant R..
AQ
05/18NOVARTIS : Sandoz announces plans to further strengthen its antibiotics manufact..
AQ
05/18NOVARTIS : reaches milestone delivery of 1 billion courses of antimalarial treat..
PU
05/03NOVARTIS : Sandoz confirms late-stage clinical development plans for proposed bi..
AQ
04/28NOVARTIS : ESG Update - April 28, 2021 (PDF 0.3 MB)
PU
04/27NOVARTIS : Q1 Earnings Snapshot
AQ
04/27NOVARTIS : Q1 2021 Results Investor presentation
PU
04/27NOVARTIS : Interim financial report (PDF 0.4 MB)
PU
04/23NOVARTIS : to initiate SMART Phase 3b global study of Zolgensma in children up t..
PU
04/19NOVARTIS : Kesimpta (ofatumumab) data at AAN showed reduction in disability prog..
AQ
04/16NOVARTIS : Kesimpta® (ofatumumab) data at AAN showed reduction in disability pro..
PU
04/15NOVARTIS : signs initial agreement to reserve capacity and implement the technol..
PU
04/13ERASMUS UNIVERSITY ROTTERDAM : A bifurcated approach to labour market integratio..
AQ
03/31NOVARTIS : expands targeted radioligand therapy pipeline with in-license for com..
AQ
03/31GENMAB A/S : Announces European Marketing Authorization for Kesimpta in Relapsin..
AQ
03/30NOVARTIS : receives EU approval for Kesimpta® (ofatumumab), the first and only s..
PU
03/24Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Co..
AQ
03/24NOVARTIS : statement on comment in Swiss media
PU
03/23NOVARTIS INDIA : inaugurates innovative watershed project in India to increase w..
AQ
03/18NOVARTIS : awards $450,000 to eight nonprofit organizations through the STEP Pro..
AQ
03/10NOVARTIS : provides update on Phase III study evaluating canakinumab as second o..
AQ
03/08NOVARTIS : Challenging a young scientist to focus on patients
AQ
03/04NOVARTIS : signs initial agreement with CureVac to manufacture COVID-19 vaccine ..
PU
03/03NOVARTIS AG : - Novartis shareholders approve all resolutions proposed by the Bo..
AQ
03/01BEIGENE : Announces Closing of Collaboration with Novartis to Develop and Commer..
AQ
03/01NOVARTIS : Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in..
AQ
03/01BEIGENE : Novartis strengthens Oncology pipeline with successful closing of tisl..
AQ
02/26NOVARTIS : strengthens Oncology pipeline with successful closing of tislelizumab..
PU
02/26NOVARTIS : Federal Court Holds Section 8.2 Of The PMNOC Regulations Does Not Imp..
AQ
02/26NOVARTIS : Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data i..
PU
02/19NOVARTIS : Gates Foundation to fund Novartis' development of a sickle cell disea..
AQ
02/18NOVARTIS : and the Bill and Melinda Gates Foundation collaborate to discover and..
AQ
02/17NOVARTIS : data show multiple sclerosis patients and nurses prefer Kesimpta Sens..
AQ
02/17NOVARTIS : Entresto granted expanded indication in chronic heart failure by FDA
AQ
02/16NOVARTIS : data show multiple sclerosis patients and nurses prefer Kesimpta® (of..
PU
02/11NOVARTIS : Sandoz announces agreement to acquire GSK's cephalosporin antibiotics..
AQ
02/09NOVARTIS : receives FDA Breakthrough Therapy designations for investigational ST..
AQ
02/08NOVARTIS : receives FDA Breakthrough Therapy designations for investigational ST..
PU
02/02NOVARTIS : Federal Court Upholds Validity Of Two Patents Pertaining To ELIQUIS
AQ
02/01NOVARTIS : renews WHO medicine donation pledge with aim of ending leprosy
AQ
02/01GENMAB A/S : - CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing..
AQ
02/01BIONTECH : Novartis signs initial agreement to provide manufacturing capacity fo..
AQ
01/29NOVARTIS : signs initial agreement to provide manufacturing capacity for Pfizer-..
PU
01/29NOVARTIS : renews WHO medicine donation pledge with aim of ending leprosy
PU
01/26NOVARTIS : 4Q Earnings Snapshot
AQ
01/26NOVARTIS : Annual Review 2020
PU
01/26NOVARTIS : Access our interactive slide deck (PDF 12 MB)
PU
01/26NOVARTIS : Download the investor presentation
PU
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
01/19NOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
01/13NOVARTIS : Prosecution History Cannot Be Invoked Against Patent Licensees
AQ
01/11NOVARTIS : Federal Court Clarifies Admissibility Of Prosecution History Evidence..
AQ
2020NOVARTIS : Strict 45-Day Time Limit For Starting PMNOC Action Was Suspended By C..
AQ
2020NOVARTIS : investigational oral therapy iptacopan receives FDA Breakthrough Ther..
AQ
2020NOVARTIS : builds on commitment to addressing need in neuropsychiatric disorders..
PU
2020NOVARTIS : reports positive topline results from second Phase III trial of Beovu..
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on NOVARTIS AG